Office of Technology Development - Sponsored Research Agreements Join us as we congratulate the Principal Investigators of new industry sponsored research agreements listed below. (Based on information available as of 2/3/11): January 2011 Principal Investigator: Matthew G. Fury, MD, PhD Department/Program: Medicine/Head and Neck Oncology Service Project Title: Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients with Advanced Solid Tumors. Total Award Amount: $271,177 Award Date: 01/04/11 Awarding Agency: Novartis Pharmaceuticals Corporation Principal Investigator: Lee M. Krug, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: Phase II Study of ADI-PEG 20 in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer Total Award Amount: $150,544 Award Date: 01/08/11 Awarding Agency: Ludwig Institute for Cancer Research Principal Investigator: Craig Moskowitz, MD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults with Relapsed or Refractory Hodgkin Lymphoma Total Award Amount: $96,467 Award Date: 01/20/11 Awarding Agency: Plexxikon Inc. Principal Investigator: Eileen O'Reilly, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-101 for Infustion as a Second-Line Therapy for Gemcitabine Refractory Patients with Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression Total Award Amount: $171,261 Award Date: 01/12/11 Awarding Agency: Clovis Oncology Principal Investigator: Antonio M. Omuro, MD Department/Program: Neurology/Neurology Service Project Title: An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects with Recurrent Glioblastoma Who Are Candidates for Surgical Resection Total Award Amount: $168,422 Award Date: 01/20/11 Awarding Agency: Exelixis, Inc. Principal Investigator: Dana Rathkopf, MD, PhD Department/Program: Medicine / Genitourinary Oncology Service Project Title: A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors Total Award Amount: $392,849 Award Date: 01/07/11 Awarding Agency: Exelixis, Inc. Principal Investigator: Dana Rathkopf, MD, PhD Department/Program: Medicine / Genitourinary Oncology Service Project Title: A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors Total Award Amount: $34,124 Award Date: 01/12/11 Awarding Agency: Exelixis, Inc. Principal Investigator: Naiyer A. Rizvi, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI-3617, a Fully Human Monoclonal Antibody Directed Against ANG2, in Adult Subjects with Advanced Solid Tumors. Total Award Amount: $225,193 Award Date: 01/11/11 Awarding Agency: MedImmune Principal Investigator: Gary Schwartz, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ALN-VSP02 in Patients with Advanced Solid Tumors with Liver Involvement. Total Award Amount: 260,061 Award Date: 01/18/11 Awarding Agency: Alnylam Pharmaceuticals, Inc. Principal Investigator: Andrew D. Seidman, MD Department/Program: Medicine/Breast Cancer Medicine Service Project Title: A Phase II Study of Tesetaxel as First-Line Therapy for Subjects with Metastatic Breast Cancer Total Award Amount: $232,781 Award Date: 01/25/11 Awarding Agency: Genta Incorporated February 2011 Principal Investigator: Hani Hassoun, MD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: A Phase II, Multi-Center, Non-Randomized, Open-Label Study of TK1258 in Patients with Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4; 14) Translocation Total Award Amount: $129,585 Award Date: 02/10/11 Awarding Agency: Novartis Pharmaceuticals Corporation Principal Investigator: Nicole Lamanna, MD Department/Program: Medicine/Leukemia Service Project Title: A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Total Award Amount: $230,639 Award Date: 02/18/11 Awarding Agency: Veeda Oncology/ Calistoga Pharmaceuticals, Inc. Principal Investigator: Michael Morris, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer who Have Progressed After Taxane-Based Chemotherapy Total Award Amount: $171,279 Award Date: 02/17/11 Awarding Agency: Cougar Biotechnology, Inc Principal Investigator: Elizabeth A. Morris, MD, FACR Department/Program: Radiology/Breast Imaging Service Project Title: An Open Label, Multi-center, Phase 3 Study with Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist) in Patients with Newly diagnosed Breast Cancer Referred for Contrast-Enhanced Breast MRI Total Award Amount: $147,231.90 Award Date: 02/01/11 Awarding Agency: Bayer Corporation Principal Investigator: Michael Morris, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC Coordinating Center. Phase 2 Study of a Single Agent Tesetaxel in Chemotherapy-Naive and Chemotherapy Exposed Patients who have Progressive, Castration-Resistant Prostrate Cancer. Total Award Amount: $114,436.30 Award Date: 02/09/11 Awarding Agency: Genta Incorporated Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC CC Service Agreement Total Award Amount: $35,167 Award Date: 02/01/11 Awarding Agency: Enzon, Inc. Principal Investigator: Tanya M. Trippett, MD Department/Program: Pediatrics Project Title: IIS: A Phase I/II Clinical Study of Vorinostat in Combination with Etoposide in Pediatric Patient Total Award Amount: $30,428 Award Date: 02/09/11 Awarding Agency: Merck & Co March 2011 Principal Investigator: Paul B. Chapman, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Phase II Open-Label, Two-Cohort, Multicenter Study of GSK2118436 as a Single Agent in Treatment Naive and Previously Treated Subjects with BRAF Mutation- Positive Metastatic Melanoma to the Brain Total Award Amount: $217,110 Award Date: 03/02/11 Awarding Agency: GlaxoSmithKline Principal Investigator: Daniel C. Danila, MD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: A Phase 1 aJ1 b, Open-Label Study Evaluating the Safety and Tolerability of EZN-4176, an Androgen Receptor mRNA Antagonist, in Adult Patients with Castration- Resistant Prostate Cancer Total Award Amount: $692,267 Award Date: 03/01/11 Awarding Agency: Enzon, Inc. Principal Investigator: Steven M. Horwitz, MD Department/Program: Medicine/Lymphoma Service Project Title: Physician Registry Study Total Award Amount: $233,759 Award Date: 03/29/11 Awarding Agency: Allos Therapeutics, Inc. Principal Investigator: Nancy E. Kemeny, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients with Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer Total Award Amount: $406,900 Award Date: 03/07/11 Awarding Agency: Amgen Inc. Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC CC Service Agreement Total Award Amount: $136,037 Award Date: 03/03/11 Awarding Agency: Abbott Laboratories Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: Lab Service Agreement Related to CT EZN 4176 Total Award Amount: $682,851 Award Date: 03/18/11 Awarding Agency: Enzon, Inc. Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC CC Service Agreement Total Award Amount: $76,463 Award Date: 03/19/11 Awarding Agency: Millennium Pharmaceuticals, Inc. Principal Investigator: Leonard H. Wexler, MD Department/Program: Pediatrics Project Title: A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer Total Award Amount: $50,000 Award Date: 03/30/11 Awarding Agency: Bristol-Myers Squibb/National Cancer Institute April 2011 Principal Investigator: Ellin Berman, MD Department/Program: Medicine/Leukemia Service Project Title: A Pivotal Phase 2 Trial of AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Total Award Amount: $299,983 Award Date: 04/05/11 Awarding Agency: ARIAD Pharmaceuticals, Inc./Industrial Agreements Principal Investigator: Jorge A. Carrasquillo, MD Department/Program: Radiology/Nuclear Medicine Service Project Title: ImmunoPET Research Collaboration Agreement Total Award Amount: $26,076 Award Date: 04/28/11 Awarding Agency: Genentech, Inc. Principal Investigator: Paul B. Chapman, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Phase III Randomized, Open-Label Study Comparing GSK2118436